Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo pill aims to tackle obesity and diabetes together

NCT ID NCT06603571

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests two drugs, LY3841136 and tirzepatide, alone or together, to help adults with obesity or overweight and type 2 diabetes lose weight. About 350 participants will take the drugs or a placebo for up to 64 weeks. The goal is to see if these treatments are safe and effective for chronic weight management.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

367 people

The number who actually took part.

Started

Sep 2024

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: W8M-MC-LAA2 * Have a Body Mass Index (BMI) of ≥27 kilograms per square meter (kg/m²) * Have Type 2 Diabetes * Have a HbA1c ≥7.0 % (53 millimoles/mole (mmol/mol)) to ≤10.5% (91 mmol/mol) and treated with diet and exercise alone or with a stable dose of metformin (and not more than the locally approved dose) with or without a sodium-glucose cotransporter 2 (SGLT2) inhibitor for at least 3 months prior to screening W8M-MC-CWMM: * Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss) Exclusion Criteria: W8M-MC-LAA2 * Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening * Have an on-going or history of bradyarrhythmia and/or sinus bradycardia * Have an elevated resting pulse rate (mean \>100 beats per minute (bpm)) or reduced resting pulse rate (mean \<60 bpm) at screening * Have any of the following cardiovascular conditions within 6 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure * Have renal impairment measured as estimated glomerular filtration rate (eGFR) \<45 milliliters per minute (mL/min)/1.73 m2 * Have a history of acute or chronic pancreatitis * Have fasting triglycerides \>500 milligrams per deciliter (mg/dL) (5.7 mmol/L) at screening * All concomitant medications should be at a stable dose for at least 3 months prior to screening W8M-MC-CWMM * Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening. * Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma. * Have poorly controlled hypertension. * Have a history of symptomatic gallbladder disease within the past 2 years * Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease. * Have a lifetime history of suicide attempts.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

Contacts and locations

Locations

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

    Troy, Michigan, 48098, United States

  • CTI Clinical Research Center

    Cincinnati, Ohio, 45212, United States

  • Central Washington Health Services Association d/b/a Confluence Health

    Wenatchee, Washington, 98801, United States

  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

    Buenos Aires, C1425AGC, Argentina

  • Centro Médico Viamonte

    Buenos Aires, C1120AAC, Argentina

  • Centro de Investigaciones Metabólicas (CINME)

    Buenos Aires, C1056ABI, Argentina

  • Charter Research - Lady Lake

    The Villages, Florida, 32162, United States

  • Charter Research - Winter Park

    Orlando, Florida, 32803, United States

  • Clinvest Headlands Llc

    Springfield, Missouri, 65807, United States

  • Consultorio de Investigación Clínica EMO SRL

    Buenos Aires, C1405BUB, Argentina

  • Cotton O'Neil Diabetes & Endocrinology

    Topeka, Kansas, 66606, United States

  • Dent Neurologic Institute

    Amherst, New York, 14226, United States

  • Diablo Clinical Research, Inc.

    Walnut Creek, California, 94598, United States

  • Endeavor Clinical Trials

    San Antonio, Texas, 78240, United States

  • FutureSearch Trials of Dallas

    Dallas, Texas, 75251, United States

  • Great Lakes Clinical Trials - Andersonville

    Chicago, Illinois, 60640, United States

  • Great Lakes Clinical Trials - Ravenswood

    Chicago, Illinois, 60640, United States

  • HOPE Research Institute

    Phoenix, Arizona, 85032, United States

  • Headlands Research - Detroit

    Southfield, Michigan, 48034, United States

  • Headlands Research - Scottsdale

    Scottsdale, Arizona, 85260, United States

  • IMA Clinical Research Austin

    Austin, Texas, 78745, United States

  • Indago Research & Health Center, Inc

    Hialeah, Florida, 33012, United States

  • Iowa Diabetes and Endocrinology Research Center

    West Des Moines, Iowa, 50266, United States

  • Knownwell

    Needham, Massachusetts, 02492, United States

  • Las Vegas Medical Research

    Las Vegas, Nevada, 89128, United States

  • Lucas Research, Inc

    Morehead City, North Carolina, 28557, United States

  • Lucas Research, Inc.

    New Bern, North Carolina, 28562, United States

  • Lucida Clinical Trials

    New Bedford, Massachusetts, 02740, United States

  • Medical Research Partners

    Ammon, Idaho, 83406, United States

  • Medication Management

    Greensboro, North Carolina, 27405, United States

  • Monroe Biomedical Research

    Monroe, North Carolina, 28112, United States

  • New Horizon Research Center

    Miami, Florida, 33165, United States

  • NorCal Medical Research, Inc

    Greenbrae, California, 94904, United States

  • North Suffolk Neurology

    Port Jefferson Station, New York, 11776, United States

  • NorthShore University Health System

    Skokie, Illinois, 60077, United States

  • Northeast Research Institute (NERI)

    Fleming Island, Florida, 32003, United States

  • Peninsula Research Associates

    Rolling Hills Estates, California, 90274, United States

  • PlanIt Research, PLLC

    Houston, Texas, 77079, United States

  • Quality Medical Research

    Nashville, Tennessee, 37211, United States

  • Rochester Clinical Research, LLC

    Rochester, New York, 14609, United States

  • Spectrum Medical, Inc.

    Danville, Virginia, 24541, United States

  • Stamford Therapeutics Consortium

    Stamford, Connecticut, 06905, United States

  • StudyMetrix Research

    City of Saint Peters, Missouri, 63303, United States

  • Suncoast Clinical Research, Inc.

    New Port Richey, Florida, 34652, United States

  • Tekton Research - Fredericksburg Road

    San Antonio, Texas, 78229, United States

  • Texas Valley Clinical Research

    Weslaco, Texas, 78596, United States

  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa

    Chandler, Arizona, 85225, United States

  • The Institute for Liver Health II dba Arizona Liver Health-Tucson

    Tucson, Arizona, 85712, United States

  • Tribe Clinical Research, LLC

    Greenville, South Carolina, 29607, United States

  • Velocity Clinical Research, Dallas

    Dallas, Texas, 75230, United States

  • Velocity Clinical Research, Huntington Park

    Huntington Park, California, 90255, United States

  • Velocity Clinical Research, Syracuse

    East Syracuse, New York, 13057, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.